|
1
|
Xiu AX, Hong TS, Hezel AF and Kooby DA:
Current management of gallbladder carcinoma. Oncologist.
15:168–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valle JW, Wasan H, Palmer DH, Cunningham
D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S,
Pereira SP, et al: Cisplatin plus gemcitabine versus gemcitabine
for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gelmon K: The toxoids: Paclitaxel and
docetaxel. Lancet. 344:1267–1272. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Donaldson KL, Goolsby GL, Kiener PA and
Wahl AF: Activation of p34cdc2 coincident with taxol-induced
apoptosis. Cell Growth Differ. 5:1041–1050. 1994.PubMed/NCBI
|
|
5
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang D, Sun L, Xian W, Liu F, Ling G,
Xiao L, Liu Y, Peng Y, Haruna Y and Kanwar YS: Low-dose paclitaxel
ameliorates renal fibrosis in rat UUO model by inhibition of
TGF-beta/Smad activity. Lab Invest. 90:436–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou J, Zhong DW, Wang QW, Miao XY and Xu
XD: Paclitaxel ameliorates fibrosis in hepatic stellate cells via
inhibition of TGF-beta/Smad activity. World J Gastroenterol.
16:3330–3334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hirose A, Tajima H, Ohta T, Tsukada T,
Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H,
et al: Low-dose paclitaxel inhibits the induction of
epithelial-mesenchymal transition in the human cholangiocarcinoma
CCKS-1 cell line. Oncol Lett. 6:915–920. 2013.PubMed/NCBI
|
|
9
|
Tajima H, Ohta T, Shinbashi H, Hirose A,
Tsukada T, Okamoto K, Nakanuma S, Sakai S, Furukawa H, Makino I, et
al: Successful treatment of unresectable gallbladder cancer with
low-dose paclitaxel as palliative chemotherapy after failure of
gemcitabine and oral S-1: A case report. Oncol Lett. 4:1281–1284.
2012.PubMed/NCBI
|
|
10
|
Eienhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ellis PA, Norman A, Hill A, O'Brien ME,
Nicolson M, Hickish T and Cunningham D: Epirubicin, cisplatin and
infusional 5-fluoroufacil (5-FU) (ECF) in hepatobiliary tumors. Eur
J Cancer. 31A:1594–1598. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patt YZ, Jones DV Jr..Hoque A, Lozano R,
Markowitz A, Raijman I, Lynch P and Charnsangavej C: Phase II trial
of intravenous fluorouracil and subcutaneous interferon alfa-2b for
biliary tract cancer. J Clin Oncol. 14:2311–2315. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomized,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Papakostal P, Kouroussis C, Androulakis N,
Samelis G, Aravantinos G, Kalbakis K, Sarra E, Souglakos J,
Kakolyris S and Georgoulias V: First-line chemotherapy with
docetaxel for unresectable or metastatic carcinoma of the biliary
tract. A multicentre phase II study. Eur J Cancer. 37:1833–1838.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Okada S, Sakata Y, Matsuno S, Kurihara M,
Sasaki Y, Ohashi Y and Taguchi T: Phase II study of docetacel in
patients with metastatic pancreatic cancer: A Japanese cooperative
study. Cooperative Group of Docetaxel for Pancreatic Cancer in
Japan. Br J Cancer. 80:438–443. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ryan DP, Kulke MH, Fuchs CS, Grossbard ML,
Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ and
Clark JW: A Phase II study of gemcitabine and docetaxel in patients
with metastatic pancreatic carcinoma. Cancer. 94:97–103. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jones DV Jr..Lozano R, Hoque A, Markowitz
A and Patt YZ: Phase II study of paclitaxel therapy for
unresectable biliary tree carcinomas. J Clin Oncol. 14:2306–2310.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maeda S, Motoi F, Onogawa T, Morikawa T,
Shigeru O, Sakata N, Takadate T, Naitoh T, Rikiyama T, Katayose Y,
et al: Paclitaxel as second-line chemotherapy in patients with
gemcitabine-refractory pancreatic cancer: A retrospective study.
Int J Clin Oncol. 16:539–545. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beak I, Bai CZ, Hwang J, Nam HY, Park JS
and Kim DJ: Paclitaxel coating of the luminal surface of
hemodialysis grafts with effective suppression of neointimal
hyperplasia. J Vasc Surg. 55:806–814.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi HS, Savard CE, Choi JW, Kuver R and
Lee SP: Paclitaxel interrupts TGF-beta1 signaling between
gallbladder epithelial cells and myofibroblasts. J Surg Res.
141:183–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Taghian AG, Abi-Raad R, Assaad SI, Casty
A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I,
et al: Paclitaxel decreases the interstitial fluid pressure and
improve oxygenation in breast cancer in patients treated with
neoadjuvant chemotherapy: Clinical implications. J Clin Oncol.
23:1951–1961. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Von Hoff DD, Ramanthan RK, Borad MJ,
Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias
JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in
patients with advanced pancreatic cancer: A phase I/II trial. J
Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alvarez R, Musteanu M, Garcia-Garcia E,
Lopez-Casas PP, Megias D, Guerra C, Muňoz M, Quijano Y, Cubillo A,
Rodoriguez-Pascual J, et al: Stromal disrupting effects of
nab-paclitaxel in pancreatic cancer. Br J Cancer. 109:926–933.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shukuya T, Yasui H, Boku N, Onozawa Y,
Fukutomi A, Yamazaki K, Taku K, Kojima T and Machida N: Weekly
paclitaxel after failure of gemcitabine in pancreatic cancer
patients with malignant ascites: A retrospective study. Jpn J Clin
Oncol. 40:1135–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cereda S and Reni M: Weekly docetaxel as
salvage therapy in patients with gemcitabine-refractory metastatic
pancreatic cancer. J Chem. 20:509–512. 2008.
|
|
27
|
Tajima H, Ohta T, Makino I, Hayashi H,
Nakagawara H, Onishi I, Takamura H, Ninomiya I, Kitagawa H, Fushida
S, et al: Expression of epithelial-mesenchymal transition markers
in locally recurrent hepatocellular carcinoma after radiofrequency
ablation. Exp Therap Med. 1:347–350. 2010.
|
|
28
|
Schrama JG, de Boer MM, Baars JW,
Schornagel JH and Rodenhuis S: Palliative chemotherapy after
failure of high-dose chemotherapy in breast cancer-toxicity and
efficacy. Anticancer Res. 23:2795–2800. 2003.PubMed/NCBI
|
